EM Breakout -- Add Exposure
The laundry list of current market conditions consistent with the profile of a bull market continues to grow, helping support our ongoing belief...
925 Views
Japan Pharma - Domestic Market and Long Listed Drug Exposure
The Japanese government recently announced its decision to initiate an ad-hoc price reduction of ~4.35%, to be levied in October 2019, this will...
1.2k Views
Japan Pharma - Top Picks
While Gni Group Ltd (2160 JP) is our high risk-high return pick, Mitsubishi Tanabe Pharma (4508 JP) Â is a contrarian call in anticipation of value...
771 Views
Independent Director Is a Great Way to Supplement Retirement in Japan....
We all know that Japan has tried to give the impression that they are improving corporate governance. However, when you start to dig into the...
700 Views
Japan Pharma: Core Coverage Investment Thesis and Valuations (III/​III)
Takeda Pharmaceutical (4502 JP), Astellas Pharma (4503 JP), Daiichi Sankyo (4568 JP), Eisai Co Ltd (4523 JP), Otsuka Holdings (4578 JP), Chugai...
513 Views